In-hospital heart rate reduction and its relation to outcomes of heart failure patients with sinus rhythm: Results from the Polish part of the European Society of Cardiology Heart Failure Pilot and Long-Term Registries.


Journal

Cardiology journal
ISSN: 1898-018X
Titre abrégé: Cardiol J
Pays: Poland
ID NLM: 101392712

Informations de publication

Date de publication:
2020
Historique:
received: 05 02 2018
accepted: 07 07 2018
revised: 07 07 2018
pubmed: 30 8 2018
medline: 8 6 2021
entrez: 30 8 2018
Statut: ppublish

Résumé

Currently, there is no information on whether in-hospital heart rate (HR) reduction has an influence on risk of death or rehospitalization. The study evaluates the relation between inhospital HR reduction in heart failure (HF) patients on mortality and rehospitalization within 1-year observation. The analysis included patients hospitalized in Poland with sinus rhythm from the European Society of Cardiology Heart Failure Pilot (ESC-HF-Pilot) and ESC Heart Failure Long-Term Registries (ESC-HF-LT), who were divided into two groups: reduced HR and not-reduced HR. HR reduction was defined as a reduced value of HR at discharge compared to admission HR. The primary endpoint was 1-year all-cause death, the secondary endpoint was 1-year all-cause death or rehospitalization for worsening HF. The final analysis included 747 patients; 491 reduced HR (65.7%) and 256 not-reduced HR (34.3%). The primary endpoint occurred in 58/476 (12.2%) from reduced HR group and in 26/246 (10.5%) from not-reduced HR group (p = 0.54). In the reduced HR group, independent predictors of primary endpoint were age, New York Heart Association class at admission, serum sodium level at admission and systolic blood pressure at discharge. In the not-reduced HR group the independent predictor of primary endpoint was diastolic blood pressure at discharge. The secondary endpoint was observed in 180 patients, 124/398 (31.2%) from reduced HR and 56/207 (27.1%) from the not-reduced HR group (p = 0.30). In the not-reduced HR group only angiotensin converting-enzyme inhibitor usage at discharge was independently associated with lower risk of the secondary endpoint. In-hospital HR reduction did not influence on the outcomes of HF patients in sinus rhythm.

Sections du résumé

BACKGROUND
Currently, there is no information on whether in-hospital heart rate (HR) reduction has an influence on risk of death or rehospitalization. The study evaluates the relation between inhospital HR reduction in heart failure (HF) patients on mortality and rehospitalization within 1-year observation.
METHODS
The analysis included patients hospitalized in Poland with sinus rhythm from the European Society of Cardiology Heart Failure Pilot (ESC-HF-Pilot) and ESC Heart Failure Long-Term Registries (ESC-HF-LT), who were divided into two groups: reduced HR and not-reduced HR. HR reduction was defined as a reduced value of HR at discharge compared to admission HR. The primary endpoint was 1-year all-cause death, the secondary endpoint was 1-year all-cause death or rehospitalization for worsening HF.
RESULTS
The final analysis included 747 patients; 491 reduced HR (65.7%) and 256 not-reduced HR (34.3%). The primary endpoint occurred in 58/476 (12.2%) from reduced HR group and in 26/246 (10.5%) from not-reduced HR group (p = 0.54). In the reduced HR group, independent predictors of primary endpoint were age, New York Heart Association class at admission, serum sodium level at admission and systolic blood pressure at discharge. In the not-reduced HR group the independent predictor of primary endpoint was diastolic blood pressure at discharge. The secondary endpoint was observed in 180 patients, 124/398 (31.2%) from reduced HR and 56/207 (27.1%) from the not-reduced HR group (p = 0.30). In the not-reduced HR group only angiotensin converting-enzyme inhibitor usage at discharge was independently associated with lower risk of the secondary endpoint.
CONCLUSIONS
In-hospital HR reduction did not influence on the outcomes of HF patients in sinus rhythm.

Identifiants

pubmed: 30155862
pii: VM/OJS/J/57253
doi: 10.5603/CJ.a2018.0094
pmc: PMC8086505
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

25-37

Références

Pol Arch Med Wewn. 2016 Aug 11;126(7-8):502-13
pubmed: 27510261
Am Heart J. 1987 Jun;113(6):1489-94
pubmed: 3591616
Circ Heart Fail. 2014 Jan;7(1):12-20
pubmed: 24297690
Circ Heart Fail. 2015 Sep;8(5):871-9
pubmed: 26243796
Lancet. 2010 Sep 11;376(9744):886-94
pubmed: 20801495
Eur J Heart Fail. 2010 Oct;12(10):1076-84
pubmed: 20805094
Int J Cardiol. 2015 Mar 1;182:426-30
pubmed: 25596471
Eur J Heart Fail. 2017 Jan;19(1):54-65
pubmed: 27790816
Lancet. 2008 Sep 6;372(9641):807-16
pubmed: 18757088
J Card Fail. 2010 Oct;16(10):806-11
pubmed: 20932462
Cardiol J. 2014;21(4):425-33
pubmed: 24142684
Eur J Heart Fail. 2013 Jul;15(7):808-17
pubmed: 23537547
Am J Cardiol. 2016 Aug 15;118(4):535-42
pubmed: 27374606
Eur Heart J. 2008 May;29(10):1327-34
pubmed: 18375982
Kardiol Pol. 2016;74(1):9-17
pubmed: 26101021
Circulation. 2001 Mar 13;103(10):1428-33
pubmed: 11245648
JACC Heart Fail. 2013 Dec;1(6):488-96
pubmed: 24622000
Am J Cardiol. 2013 Apr 1;111(7):1019-25
pubmed: 23312128
Eur Heart J. 2006 Jan;27(1):65-75
pubmed: 16219658
Eur J Heart Fail. 2016 Jun;18(6):613-25
pubmed: 27324686
Am Heart J. 2013 Apr;165(4):567-574.e6
pubmed: 23537974
Lancet. 2008 Sep 6;372(9641):817-21
pubmed: 18757091
Am Heart J. 2006 Feb;151(2):444-50
pubmed: 16442912
Int J Cardiol. 2014 Jan 15;171(1):98-100
pubmed: 24342405
J Am Heart Assoc. 2015 Apr 22;4(4):
pubmed: 25904590
Open Access Maced J Med Sci. 2016 Sep 15;4(3):435-438
pubmed: 27703569

Auteurs

Paweł Balsam (P)

1st Chair and Depar tment of Cardiology, Medical University of Warsaw, Poland.

Michał Peller (M)

1st Chair and Depar tment of Cardiology, Medical University of Warsaw, Poland. michalpeller@gmail.com.

Sonia Borodzicz (S)

1st Chair and Depar tment of Cardiology, Medical University of Warsaw, Poland.

Agnieszka Kapłon-Cieślicka (A)

1st Chair and Depar tment of Cardiology, Medical University of Warsaw, Poland.

Krzysztof Ozierański (K)

1st Chair and Depar tment of Cardiology, Medical University of Warsaw, Poland.

Agata Tymińska (A)

1st Chair and Depar tment of Cardiology, Medical University of Warsaw, Poland.

Michał Marchel (M)

1st Chair and Depar tment of Cardiology, Medical University of Warsaw, Poland.

Maria G Crespo-Leiro (MG)

Unidad de Insuficiencia Car diaca Avanzada y Trasplante Cardiaco, Hospital Universitario A Cor una, CIBERCV, La Coruna, Spain.

Aldo Pietro Maggioni (AP)

ANMCO Research Center, Florence, Italy.
EURObservational Research Programme, European Society of Car diology, Sophia-Antipolis, France.

Jarosław Drożdż (J)

Department of Cardiology, Medical University, Lodz, Poland.

Marcin Grabowski (M)

1st Chair and Depar tment of Cardiology, Medical University of Warsaw, Poland.

Krzysztof J Filipiak (KJ)

1st Chair and Depar tment of Cardiology, Medical University of Warsaw, Poland.

Grzegorz Opolski (G)

1st Chair and Depar tment of Cardiology, Medical University of Warsaw, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH